Abcuro reels in $155M to test an­ti­body's po­ten­tial in rare mus­cle dis­ease, set­ting biotech's 2026 BLA plans

Mass­a­chu­setts biotech Abcuro has se­cured $155 mil­lion to take its bi­o­log­ic through a po­ten­tial­ly reg­is­tra­tional tri­al for a rare mus­cle-wast­ing dis­ease and to an an­tic­i­pat­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER